Home/Filings/4/0001415889-25-023701
4//SEC Filing

Naos Yaron 4

Accession 0001415889-25-023701

CIK 0001006281other

Filed

Sep 3, 8:00 PM ET

Accepted

Sep 4, 5:00 PM ET

Size

9.4 KB

Accession

0001415889-25-023701

Insider Transaction Report

Form 4
Period: 2025-09-03
Naos Yaron
Sr. VP, Operations
Transactions
  • Award

    Common Stock

    2025-09-03+25,000225,817 total(indirect: By Trust)
  • Award

    Stock Option (Right to Buy)

    2025-09-03+50,00050,000 total
    Exercise: $1.64Exp: 2035-09-03Common Stock (50,000 underlying)
Holdings
  • Common Stock

    7,112
Footnotes (4)
  • [F1]Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
  • [F2]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.
  • [F3]The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
  • [F4]Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034.

Issuer

Protalix BioTherapeutics, Inc.

CIK 0001006281

Entity typeother

Related Parties

1
  • filerCIK 0001742727

Filing Metadata

Form type
4
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 5:00 PM ET
Size
9.4 KB